Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Receivables for 9 consecutive years, with $47.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 37.41% to $47.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.2 million, a 37.41% increase, with the full-year FY2025 number at $47.2 million, up 37.41% from a year prior.
  • Receivables was $47.2 million for Q4 2025 at Akebia Therapeutics, down from $66.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $91.4 million in Q2 2022 to a low of $18.2 million in Q1 2023.
  • A 5-year average of $44.7 million and a median of $39.2 million in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: surged 2207.6% in 2021, then plummeted 78.59% in 2023.
  • Akebia Therapeutics' Receivables stood at $55.9 million in 2021, then decreased by 24.52% to $42.2 million in 2022, then rose by 1.04% to $42.6 million in 2023, then fell by 19.37% to $34.4 million in 2024, then skyrocketed by 37.41% to $47.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Receivables are $47.2 million (Q4 2025), $66.2 million (Q3 2025), and $78.2 million (Q2 2025).